0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

Patient FAQs & demands and how to address

Session 3: The educated migraine patient

Marja Hassinen​ ​

Bachelor of Health Care & Master of Headache Disorders

Previous

Misconceptions on migraine and treatments - social media, Google, etc.

Next

New EHF guideline on the use of MAb’s for migraine prevention

You Might Also Like

Related Embedded Video Item Thumbnail Biomarkers with focus on genetics
Related Embedded Video Item Thumbnail Migraine in elderly
Related Embedded Video Item Thumbnail Comorbidities and management
Related Embedded Video Item Thumbnail Treatment response as a biomarker
Related Embedded Video Item Thumbnail Safety, tolerability and possible interactions of the MAbs

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128